(Q36681524)

15 August 2017

1 reference

title

Net clinical benefit: functional endpoints in brain tumor clinical trials (English)

1 reference

15 August 2017

1 reference

Terri S Armstrong

1

1 reference

ORCID Public Data File 2021

author name string

Mark R Gilbert

series ordinal

2

1 reference

15 August 2017

publication date

1 January 2007

1 reference

15 August 2017

published in

Current Oncology Reports

1 reference

15 August 2017

volume

9

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

60-65

1 reference

Phase II study of gemcitabine in patients with advanced pancreatic cancer

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF02951427

Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02951427

Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02951427

What do cancer patients mean when they complain of concentration and memory problems?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02951427

Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02951427

21 January 2018

1 reference

12 December 2020

Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma

1 reference

12 December 2020

Quality of life in patients with intracranial tumors on the basis of Karnofsky's performance status

1 reference

12 December 2020

The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires

1 reference

12 December 2020

A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme

1 reference

12 December 2020

Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial

1 reference

12 December 2020

Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory.

1 reference

12 December 2020

Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas.

1 reference

12 December 2020

Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT).

1 reference

12 December 2020

Brain-tumour clinical-trial endpoints: FDA public workshop

1 reference

12 December 2020

Anaplastic oligodendroglial tumors: a tale of two trials

1 reference

12 December 2020

The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity

1 reference

12 December 2020

Symptom distress as rated by advanced cancer patients, caregivers and physicians in the last week of life

1 reference

12 December 2020

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

12 December 2020

Changing paradigms--an update on the multidisciplinary management of malignant glioma

1 reference

12 December 2020

Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma

1 reference

12 December 2020

Cognitive deficits in adult patients with brain tumours

1 reference

12 December 2020

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

12 December 2020

Scientific problems in clinical scales, as demonstrated in the Karnofsky index of performance status

1 reference

12 December 2020

1 reference

12 December 2020

Symptom clusters in oncology patients and implications for symptom research in people with primary brain tumors.

1 reference

12 December 2020

Quality and duration of survival in glioblastoma multiforme. Combined surgical, radiation, and lomustine therapy

1 reference

12 December 2020

Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors

1 reference

12 December 2020

Issues in assessing and interpreting quality of life in patients with malignant glioma.

1 reference

12 December 2020

The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors.

1 reference

12 December 2020

When is it justified to treat symptoms? Measuring symptom burden.

1 reference

12 December 2020

Cognitive function as a predictor of survival in patients with recurrent malignant glioma.

1 reference

12 December 2020

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

12 December 2020

Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression

1 reference

12 December 2020

Content validity of self-report measurement instruments: an illustration from the development of the Brain Tumor Module of the M.D. Anderson Symptom Inventory.

1 reference

12 December 2020

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02951427

1 reference

15 August 2017

1 reference